Acute rejection of renal transplant

Main research purpose: This study uses mycophenolate sodium enteric-coated tablets (0.36g) produced by Chengdu Beite Pharmaceutical Co., Ltd. as the test preparation and mycophenolate sodium enteric-coated tablets (360mg, trade name: Myfortic®) produced by the original manufacturer Novartis Pharma Produktions GmbH as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation when administered under fasting and postprandial conditions. Secondary research purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.

To investigate the pharmacokinetic characteristics of a single oral administration of Mycophenol Sodium Enteric-coated Tablets (test preparation, specification: 180 mg) certified by Zhejiang Medishen Biopharmaceutical Co., Ltd. and produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd. to healthy subjects under fasting and postprandial conditions, and a single oral administration of Mycophenol Sodium Enteric-coated Tablets (reference preparation, trade name: Myfortic®, specification: 180 mg) certified by Novartis Pharma GmbH under the same conditions, to evaluate the bioequivalence and safety of the two preparations, and to provide a basis for the registration application of the test preparation.